Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 177

Sort by

Sort Order Select

Journal Articles

Analysis of the Metabolic State of Residual Multiple Myeloma Plasma Cells Reveals a Proliferative Subset with Glycolytic Gene Expression

Whitney Tevebaugh, James Douglas, MS, Brian A Walker, PhD, Carolina D. Schinke, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Faith E. Davies, MD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Gareth J. Morgan, MD PhD, Sarah K Johnson, PhD

Blood (2017) 130 (Supplement 1): 4392.

https://doi.org/10.1182/blood.V130.Suppl_1.4392.4392

Published: 2017

Journal Articles

MAFA Expression Promotes Proliferation of Myeloma Cells and Its Protein Stability Is Regulated By Proteasome Inhibitors

Ya-Wei Qiang, MD PhD, Shiqiao Ye, PhD BSc, MSc, Yu Chen, Ichiro Hanamura, MD PhD, Brian A Walker, PhD, Gareth J. Morgan, MD PhD, Faith E. Davies, MD

Blood (2017) 130 (Supplement 1): 4394.

https://doi.org/10.1182/blood.V130.Suppl_1.4394.4394

Published: 2017

Journal Articles

Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial

Blood (2017) 130 (Supplement 1): 436.

https://doi.org/10.1182/blood.V130.Suppl_1.436.436

Published: 2017

Journal Articles

Spatial Genomic Heterogeneity in Multiple Myeloma: Surrogate Markers and Its Significance for Understanding the Evolutionary Processes Leading to Relapse

Leo Rasche, MD, Tobias Meissner, PhD, Grant Gershner, Cody Cody Ashby, PhD, Ruslana G. Tytarenko, MS, Owen W. Stephens, Michael Bauer, PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Brian A Walker, PhD, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Niels Weinhold, PhD

Blood (2017) 130 (Supplement 1): 4372.

https://doi.org/10.1182/blood.V130.Suppl_1.4372.4372

Published: 2017

Journal Articles

Daratumamab in High Risk Relapse/Refractory Myeloma Patients Effect of 1q21 Gain and GEP70 Status

Meera Mohan, MD, Niels Weinhold, PhD, Frits van Rhee, MD PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Leo Rasche, MD, Jeffery R. Sawyer, Erming Tian, PhD MBA, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Maurizio Zangari, MD

Blood (2017) 130 (Supplement 1): 4373.

https://doi.org/10.1182/blood.V130.Suppl_1.4373.4373

Published: 2017

Journal Articles

Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients

Blood (2017) 130 (Supplement 1): 4331.

https://doi.org/10.1182/blood.V130.Suppl_1.4331.4331

Published: 2017

Journal Articles

MYC Rearrangements in Multiple Myeloma Are Complex, Can Involve More Than Five Different Chromosomes, and Correlate with Increased Expression of MYC and a Distinct Downstream Gene Expression Pattern

Aneta Mikulasova, PhD, Cody Cody Ashby, PhD, Ruslana G. Tytarenko, MS, Michael Bauer, PhD, Konstantimos Mavrommatis, PhD, Christopher P. Wardell, PhD, Matthew Trotter, PhD, Shayu Deshpande, Owen W. Stephens, Erming Tian, PhD MBA, Graham Jackson, Faith E. Davies, MD, Anjan Thakurta, PhD, Nikhil Munshi, MD, Gareth J. Morgan, MD PhD, Brian A Walker, PhD

Blood (2017) 130 (Supplement 1): 65.

https://doi.org/10.1182/blood.V130.Suppl_1.65.65

Published: 2017

Journal Articles

Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide

Ruth M de Tute, PhD FRCPath, David Cairns, BSc, MSc, PhD, Andy Rawstron, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, John R Jones, MD, Martin F Kaiser, MD, Anna Hockaday, Alina Striha, MSc, Rowena Henderson, PhD, Gordon Cook, PhD, Nigel H. Russell, Mark T Drayson, MD PhD, Matthew W Jenner, Walter M Gregory, PhD, Graham Jackson, MDPhD, Gareth J. Morgan, MD PhD, Roger G. Owen, MD

Blood (2017) 130 (Supplement 1): 904.

https://doi.org/10.1182/blood.V130.Suppl_1.904.904

Published: 2017

Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Kwee Yong, PhD, Samantha Hinsley, Holger W. Auner, MD PhD, Debbie Sherratt, Ruth Mary De Tute, BSc,MSc, Sarah Brown, Louise Flanagan, Cathy Williams, Jamie Cavenagh, Martin F Kaiser, MD, Neil Rabin, Karthik Ramasamy, Mamta Garg, MD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Gareth J. Morgan, MD PhD, Faith E. Davies, MD, Roger G Owen, MD

Blood (2017) 130 (Supplement 1): 835.

https://doi.org/10.1182/blood.V130.Suppl_1.835.835

Published: 2017

Journal Articles

AML-Associated Somatic Mutations Can be Detected in Stem and Progenitor Populations in Patients with Antecedent Multiple Myeloma Years before Onset of Therapy-Related Transformation

Ashwin Sridharan, Carolina D. Schinke, MD, George Georgiev, Mariana Da Silva Ferreira, Kith Pradhan, PhD, Yu Xia, PhD, Maya Panjikaran, MS, Gregory Sims, Chirag Bhagat, Armin Graber, Christoph Heuck, MD, Daisy Alapat, MD, Niels Weinhold, PhD, Sarah K Johnson, PhD, Bart Barlogie, MD PhD, Gareth J. Morgan, MD PhD, Ulrich G. Steidl, MDPhD, Britta Will, PhD, Amit Verma, MD

Blood (2017) 130 (Supplement 1): 2706.

https://doi.org/10.1182/blood.V130.Suppl_1.2706.2706

Published: 2017

Journal Articles

A Meta-Analysis of Genome-Wide Association Studies of Multiple Myeloma in Persons of African Ancestry [African-American Multiple Myeloma Study (AAMMS)] Identifies Suggestive Risk Variants

Zhaohui Du, M.S., Niels Weinhold, PhD, David Van Den Berg, PhD, Amie Hwang, PhD MPH, Xin Sheng, M.S., Victor Hom, M.S., Sikander Ailawadhi, Ajay K. Nooka, MDMPH, Seema Singhal, MD, Karen Pawlish, Sc.D, M.P.H, Edward S. Peters, DMD, SM, SM, ScD, Cathryn Bock, PhD, Ann Mohrbacher, MD, Alexander Stram, M.S., Donglei Hu, M.S., John Graff, PhD, M.S., Sonja I Berndt, PhD, William J. Blot, PhD, John David Carpten, PhD, Graham Casey, PhD, Victoria L. Stevens, PhD, Rick Kittles, PhD, Goodman Phyllis, M.S., Anselm Hennis, MB;BS, MSc., PhD DLSHTM, FRCP, FACP, Eric A. Klein, MD, Barbara Nemesure, Benjamin A. Rybicki, Janet Stanford, John Witte, PhD, Christine B. Ambrosone, Esther M. John, Leslie Bernstein, PhD, M.S., Antoinette Stroup, PhD, Andrew Olshan, Wei Zheng, MD PhD, Jennifer J. Hu, Regina Ziegler, PhD, M.P.H., Sarah J. Nyante, Elisa Bandera, Sue Ann Ingles, PhD, Jayesh Mehta, MD, Graham A Colditz, MD DrPH, Michael Tomasson, MD, Mark A. Fiala, BS, Howard Terebelo, DO, Nalini Janakiraman, MD, Laurence Kolonel, MD, PhD, Loic Le Marchand, MD, PhD, Kenneth C Anderson, MD, Elad Ziv, MD, Brian C.-H. Chiu, PhD, David Conti, PhD, Daniel Stram, PhD, Ravi Vij, MDMBA, Leon Bernal-Mizrachi, MD, Jeffrey A Zonder, MD, Gareth J. Morgan, MD PhD, Carol Ann Huff, MD, Robert Z. Orlowski, MD PhD, Sagar Lonial, MD, Christopher A. Haiman, PhD, Wendy Cozen, DO,MPH

Blood (2017) 130 (Supplement 1): 3058.

https://doi.org/10.1182/blood.V130.Suppl_1.3058.3058

Published: 2017

Journal Articles

Chromosome 1q12 Instability Drives Both 1q21 Amplification and Arm-Length Deletions in Multiple Myeloma

Jeffery R. Sawyer, Erming Tian, PhD MBA, Brian A Walker, PhD, Charles M. Swanson, Janet L Lukacs, Gael M. Sammartino, Clyde Bailey, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD

Blood (2017) 130 (Supplement 1): 3060.

https://doi.org/10.1182/blood.V130.Suppl_1.3060.3060

Published: 2017

Journal Articles

The Leeds Risk Profile Predicts Outcome for Older Myeloma Patients: A Prognostic Score Using Frailty Biomarkers Derived and Tested Using 2371 Clinical Trial Patients

Gordon Cook, MD PhD, Kara-Louise Royle, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Anna Hockaday, Walter M Gregory, PhD, J Anthony Child, Faith E Davies, MD, Gareth J. Morgan, MD PhD, David Cairns, BSc, MSc, PhD, Graham Jackson, MDPhD

Blood (2017) 130 (Supplement 1): 3063.

https://doi.org/10.1182/blood.V130.Suppl_1.3063.3063

Published: 2017

Journal Articles

Whole Genome Sequencing Reveals the Extent of Structural Variants in Multiple Myeloma and Identifies Recurrent Mutational Hotspots within the Non-Coding Regions

Cody Cody Ashby, PhD, Michael Bauer, PhD, Owen W. Stephens, Christopher P. Wardell, PhD, Ruslana G. Tytarenko, MS, Aneta Mikulasova, PhD, Purvi Patel, Shayu Deshpande, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Niels Weinhold, PhD, Leo Rasche, MD, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Brian A Walker, PhD

Blood (2017) 130 (Supplement 1): 3032.

https://doi.org/10.1182/blood.V130.Suppl_1.3032.3032

Published: 2017

Journal Articles

Factors Predicting Poor Outcomes for Myeloma Patients at Different Ages: Results from 3894 Patients in the Myeloma XI Trial

Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Martin F Kaiser, MD, David Cairns, BSc, MSc, PhD, Alina Striha, MSc, John R Jones, MD, Vallari Shah, MBBS, Matthew W Jenner, Mark T Drayson, MD PhD, Roger G Owen, MD, Walter M Gregory, PhD, Gordon Cook, MD PhD, Graham Jackson, MDPhD, Gareth J. Morgan, MD PhD, Faith E Davies, MD

Blood (2017) 130 (Supplement 1): 3040.

https://doi.org/10.1182/blood.V130.Suppl_1.3040.3040

Published: 2017

Journal Articles

Clinical and Molecular Characterization of Primary Plasma Cell Leukemia

Sandra Susanibar, MD, Pingping Qu, Antje Hoering, Sharmilan Thanendrarajan, MD, Jorge Jo Kamimoto, MD, Meera Mohan, MD, Pankaj Mathur, MD, Shadiqul Hoque, MD, Muthukumar Radhakrishnan, MD, Phil Farmer, Nathan Petty, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Faith E. Davies, MD, Daisy Alapat, MD, Barlogie Bart, Gareth J. Morgan, MD PhD, Carolina D. Schinke, MD

Blood (2017) 130 (Supplement 1): 3047.

https://doi.org/10.1182/blood.V130.Suppl_1.3047.3047

Published: 2017

Journal Articles

Infectious Complications of Daratumumab-Containing Therapy for Multiple Myeloma

Andrew Johnsrud, MD, Sandra Susanibar, MD, Jorge Jo Kamimoto, MD, Joyce Johnsrud, MD, Atul Kothari, MD, Mary Burgess, MD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Frits Van Rhee, MD PhD, Juan Carlos Rico Crescencio, MD

Blood (2017) 130 (Supplement 1): 3148.

https://doi.org/10.1182/blood.V130.Suppl_1.3148.3148

Published: 2017

Journal Articles

Crowdsourcing a High-Risk Classifier for Multiple Myeloma Patients

Blood (2017) 130 (Supplement 1): 265.

https://doi.org/10.1182/blood.V130.Suppl_1.265.265

Published: 2017

Journal Articles

MAF and NF-κB Signaling Pathways Regulate Expression of APOBEC3B in Multiple Myeloma

Valeriy V Lyzogubov, MD PhD, Ruslana G. Tytarenko, MS, Cody Cody Ashby, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Brian A Walker, PhD

Blood (2017) 130 (Supplement 1): 4342.

https://doi.org/10.1182/blood.V130.Suppl_1.4342.4342

Published: 2017

Journal Articles

The Mutational Landscape of Relapse in High Risk Myeloma Is Significantly Impacted By the Depth of Response but Not Maintenance Lenalidomide

Blood (2017) 130 (Supplement 1): 396.

https://doi.org/10.1182/blood.V130.Suppl_1.396.396

Published: 2017

NARROW

Analysis of the Metabolic State of Residual Multiple Myeloma Plasma Cells Reveals a Proliferative Subset with Glycolytic Gene Expression

MAFA Expression Promotes Proliferation of Myeloma Cells and Its Protein Stability Is Regulated By Proteasome Inhibitors

Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial

Spatial Genomic Heterogeneity in Multiple Myeloma: Surrogate Markers and Its Significance for Understanding the Evolutionary Processes Leading to Relapse

Daratumamab in High Risk Relapse/Refractory Myeloma Patients Effect of 1q21 Gain and GEP70 Status

Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients

MYC Rearrangements in Multiple Myeloma Are Complex, Can Involve More Than Five Different Chromosomes, and Correlate with Increased Expression of MYC and a Distinct Downstream Gene Expression Pattern

Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

AML-Associated Somatic Mutations Can be Detected in Stem and Progenitor Populations in Patients with Antecedent Multiple Myeloma Years before Onset of Therapy-Related Transformation

A Meta-Analysis of Genome-Wide Association Studies of Multiple Myeloma in Persons of African Ancestry [African-American Multiple Myeloma Study (AAMMS)] Identifies Suggestive Risk Variants

Chromosome 1q12 Instability Drives Both 1q21 Amplification and Arm-Length Deletions in Multiple Myeloma

The Leeds Risk Profile Predicts Outcome for Older Myeloma Patients: A Prognostic Score Using Frailty Biomarkers Derived and Tested Using 2371 Clinical Trial Patients

Whole Genome Sequencing Reveals the Extent of Structural Variants in Multiple Myeloma and Identifies Recurrent Mutational Hotspots within the Non-Coding Regions

Factors Predicting Poor Outcomes for Myeloma Patients at Different Ages: Results from 3894 Patients in the Myeloma XI Trial

Clinical and Molecular Characterization of Primary Plasma Cell Leukemia

Infectious Complications of Daratumumab-Containing Therapy for Multiple Myeloma

Crowdsourcing a High-Risk Classifier for Multiple Myeloma Patients

MAF and NF-κB Signaling Pathways Regulate Expression of APOBEC3B in Multiple Myeloma

The Mutational Landscape of Relapse in High Risk Myeloma Is Significantly Impacted By the Depth of Response but Not Maintenance Lenalidomide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only